MENU
VERV
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Verve Therapeutics (VERV) Ownership - Who owns Verve Therapeutics?
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines... Show more
Profile
Industry
N/A
Address
201 Brookline Avenue
Phone
+1 617 603-0070
Employees
255
Web
https://www.vervetx.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
341.86M
P/E Ratio
N/A
Total Cash
524.28M
Projected Growth
N/A
Total Debt
69.98M
Revenue
32.33M
Risk (Beta)
1.66
Dividend Yield
N/A
Total Cash/Share
5.90
Total Debt/Equity
N/A
Revenue/Share
0.38 USD as % of share price
Fundamentals
VERV
Capitalization
342M
P/E Ratio
N/A
Risk (Beta)
1.66
Dividend Yield
N/A
Total Cash
524M
Total Cash/Share
5.90
Total Debt
70M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.38%
Revenue
32.3M
ROE
N/A
Book Value
493M
P/B Ratio
0.70
Cash Flow
N/A
Earnings
-2.35
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
89K
Current Ratio
12.65
Current Revenue Per Employee
47737.23
Dividends Per Share - Security
N/A
EBITDA
-221.91M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-28.39
Shares Held By Institutions
1.05B
Shares Outstanding - Current
88.8M
Total Liabilities
154M
Total Volume MTD
N/A
Value
1
Gain YTD
-31.826
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
201 Brookline Avenue
Phone
+1 617 603-0070
Employees
255
Web
https://www.vervetx.com